Miljöpåverkan
Karbidopa (vattenfri)
Miljörisk:
Risk för miljöpåverkan av karbidopa (vattenfri) kan inte uteslutas då det inte finns tillräckliga ekotoxikologiska data.
Nedbrytning:
Det kan inte uteslutas att karbidopa (vattenfri) är persistent, då data saknas.
Bioackumulering:
Karbidopa (vattenfri) har låg potential att bioackumuleras.
Läs mer
Detaljerad miljöinformation
Carbidopa is given in combination with levodopa used for the treatment of Parkinson's
disease and syndrome. Carbidopa is an inhibitor of aromatic amino acid decarboxylase. It is a white, crystalline compound, slightly soluble in water and very slightly soluble in alcohol.
Carbidopa has a molecular weight of 244.3 g/mole and an empirical formula of
C10H14N2O4·H2O. (Ref II)
Environmental Risk Classification
Predicted Environmental Concentration (PEC)
PEC is calculated according to the following formula:
PEC (μg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6*A(100-R)
PEC = 0.056 μg/L
Where:
A = 409.98 kg (total sold amount API in Sweden year 2021, data from IQVIA). Reduction of A may be justified based on metabolism data.
R = 0 % removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation) = 0 if no data is available. (If R not =0 this should be justified under the degradation section)
P = number of inhabitants in Sweden = 10 *106
V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Ref. I)
D = factor for dilution of wastewater by surface water flow = 10 (ECHA default) (Ref. I)
Ecotoxicological studies*
Water Flea (Daphnia magna):
Acute toxicity
EC50 48 hrs (death) = 35.3 mg/L (guideline eg OECD 202) (Reference III)
Bioaccumulation
Carbidopa has an estimated log Pow of -2.2 and therefore, has no significant bioaccumulation potential. (reference IV)
References
-
ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment. http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm
-
EPAR for Levodopa/Carbidopa Levodopa/Carbidopa/Entacapone Orion, INN- levodopa, carbidopa, entacapone (europa.eu)
-
ICI Bringham Laboratory, 1989. “Carbidopa: Determination of acute toxicity to Daphania magna” Study No Q1022/A, Brixham, England September 1989
-
HSDB for Carbidopa https://pubchem.ncbi.nlm.nih.gov/compound/34359#section=Computed-Properties
Miljöinformationen för levodopa är framtagen av företaget Roche för Larodopa, Madopark, Madopark forte, Madopark mite, Madopark®, Madopark® Depot, Madopark® Quick, Madopark® Quick mite
Miljörisk:
Användning av levodopa har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning:
Levodopa bryts ned i miljön.
Bioackumulering:
Levodopa har låg potential att bioackumuleras.
Läs mer
Detaljerad miljöinformation
Identification and characterisation
CAS number 59-92-7 [1]
Molecular weight 197.19 [1]
Brand name: Madopark, Madopark Depot, Madopark Quick, Madopark Quick mite [1]
Physico-chemical properties
Aqueous solubility 5000, >2700 mg/l [1]
Dissociation constant, pKa 2.3; 8.7; 9.7; 13.4 QSAR
Melting point 275 °C [1]
Vapour pressure 3.41E-08 Pa (25 °C) QSAR
Boiling point ND
KH 2.103E-11 Pa*m3/mol QSAR.
QSAR = QSAR-modelled (EPISuite, SPARC, ACD Solaris)
Predicted Environmental Concentration (PEC)
PEC is calculated according to the formula:
PEC (μg/L) = (A x 1'000'000'000 x (100 - R)) / (365 x P x V x D x 100) = 1.37 x 10-6 x A x (100 - R) = 0.047 μg/L
Where:
A = Sold quantity = 4270.994 kg/y sales data from IQVIA / LIF - kg consumption 2021
R = Removal rate = 92 % calculated with Simple Treat 4.0 [9]
P = Population of Sweden = 10 000 000
V = Volume of Wastewater = 200 l/day [2]
D = Factor for Dilution = 10 [2]
Predicted No Effect Concentration (PNEC)
Ecotoxicological Studies
Green alga (Pseudokirchneriella subcapitata): [5]
ErC50 72 h (growth rate) = 3.2 - 5.6 mg/l (OECD 201)
NOEC 72 h (biomass) = 0.32 mg/l (OECD 201)
In the concentration range of the ErC50, the colour of the test solutions contributed significantly to the effect on algal growth by absorbing wave lengths necessary for algal growth. The ErC50 is, therefore, an approximate value.
Water-flea (Daphnia magna): [6]
EC50 48 h (immobilisation) > 100 mg/l (OECD 202)
NOEC 48 h (immobilisation) = 100 mg/l (OECD 202)
Rainbow trout (Oncorhynchus mykiss): [7]
LC50 96 h (mortality) > 100 mg/l (OECD 203)
NOEC 96 h (mortality) = 100 mg/l (OECD 203)
Micro-organisms: [3]
NOEC (toxicity control) 28 d (endpoint) = 100 mg/l (OECD 301 F)
PNEC Derivation
The PNEC is based on the following data:
PNEC (μg/l) = lowest EC50/1000, or acute NOEC/1000, where 1000 is the assessment factor used. The lower range of the ErC50 for algae, i.e. 3.2 mg/l, has been used for this calculation. [1]
PNEC = 3200 μg/l / 1000 = 3.20 μg/l
Environmental Risk Classification (PEC/PNEC Ratio)
PEC Predicted Environmental Concentration = 0.047 μg/l
PNEC Predicted No Effect Concentration = 3.20 µg/l
Ratio PEC/PNEC = 0.015
PEC/PNEC = 0.047/3.20 = 0.015 for Levodopa which justifies the phrase 'Use of Levodopa has been considered to result in insignificant environmental risk.'
Degradation
Biotic Degradation
Ready biodegradability:
72-73% after 28 days of incubation BOD/ThOD (OECD 301 F) [3, 4]
67-70% at the end of the 10-d window BOD/ThOD (OECD 301 F) [3, 4]
98% after 28 days of incubation DOC/TOC (OECD 301 F) [3, 4]
Inherent biodegradability: ND
Other degradation information: ND
Abiotic Degradation
Photodegradation: ND
Hydrolysis: ND
Levodopa is readily biodegradable which justifies the phrase 'Levodopa is degraded in the environment.'
Bioaccumulation/Adsorption
logPOW: -2.39 EpiSuite experimental database match [8]
KOC: 1; 161 QSAR
BCF: <10 QSAR
Levodopa has low potential for bioaccumulation (log KOW <4).
Excretion/metabolism
Levodopa is rapidly absorbed after oral administration and widely distributed. Extensive metabolisaton is mainly by decarboxylation to dopamine and also by methylation to 3-O-methyldopa. Most of a dose is decarboxylated by the gastric mucosa before entering the systemic circulation, this decarboxylase activity is inhibited by co-administered benserazide. Dopamine is further metabolised to noradrenaline, 3-methoxytyramine and two major excretory metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid, HVA). About 70 to 80% of a dose is excreted by urinary pathway in 24 h, about 50% as DOPAC and HVA, 10% as dopamine, up to 30% as -O-methyldopa and less than 1% as unchanged drug. Less than 1% of a dose is eliminated in the faeces. [1]
References
1. F. Hoffmann-La Roche Ltd (2021): Environmental Risk Assessment Summary for Levodopa. https://www.roche.com/sustainability/environment/environmental-risk-assessment-downloads.htm.
2. European Medicines Agency (EMA) (2006/2015): Guideline on the environmental risk assessment of medicinal products for human use. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), 01 June 2006, EMA/CHMP/SWP/447/00 corr 2.
3. Study Report: Roche Project no. B-166335. Ready Biodegradability: Manometric Respirometry Test for Levodopa, October 1996.
4. Study Report: BMG Project no. A09-02230. Levodopa – Ready Biodegradability – Evaluation of the Aerobic Biodegradability in an Aqueous Medium: Manometric Respirometry Test, March 2010.
5. Study Report: NOTOX Project no. 180102. Fresh Water Algal Growth Inhibition Test with Levodopa, December 1996.
6. Study Report: NOTOX Project no. 180023. Acute Toxicity Study in Daphnia magna with Levodopa, December 1996.
7. Study Report: Roche Project no. B-166336. 96-Hour Acute Toxicity Test with Levodopa in Rainbow Trout, November 1996.
8. US EPA. 2012. Estimation Programs Interface Suite™ for Microsoft® Windows, v 4.11. United States Environmental Protection Agency, Washington, DC, USA.
9. Struijs (2014). SimpleTreat 4.0: a model to predict fate and emission of chemicals in wastewater treatment plants. RIVM report 601353005/2014. Model downloaded from RIVM.
ND = Not Defined